Gentamicin Sulfate · GENTAMICIN SULFATE 40 mg/mL · Injection, Solution · Intramuscular; Intravenous · Cardinal Health 107, LLC
NDC 55154-2392-05 · 5 VIAL, SINGLE-DOSE in 1 BAG / 2 mL in 1 VIAL, SINGLE-DOSE · ANDA · View full market →
8 companies supply this market — a reasonable cushion if one runs into trouble. Historically, drugs in this position went on to a new shortage within 90 days about 0.4% of the time — roughly 3× the typical drug (0.1%).
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Matched to CMS's representative package for this drug (NDC 00409-1207-03) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Not scored — fragility is computed for NADAC-priced NDCs.
sterile injectable · OAI inspection at a producing facility (24 months) · sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is 3× that.
Backtested statistical model over the whole market, not this package alone. Model details →
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Medical Purchasing Solutions, LLC | GENTAMICIN SULFATE 40 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Baxter Healthcare Corporation | GENTAMICIN SULFATE 100 mg/50mL | Jul 15, 2026 | Sep 2, 2026 |
| Baxter Healthcare Corporation | GENTAMICIN SULFATE 100 mg/100mL | Jul 15, 2026 | Sep 2, 2026 |
| Baxter Healthcare Corporation | GENTAMICIN SULFATE 60 mg/50mL | Jul 15, 2026 | Sep 2, 2026 |
| Baxter Healthcare Corporation | GENTAMICIN SULFATE 80 mg/100mL | Jul 15, 2026 | Sep 2, 2026 |
| Baxter Healthcare Corporation | GENTAMICIN SULFATE 80 mg/50mL | Jul 15, 2026 | Sep 2, 2026 |
| Cardinal Health 107, LLC | GENTAMICIN SULFATE 40 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Henry Schein, Inc | GENTAMICIN SULFATE 40 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Henry Schein, Inc. | GENTAMICIN SULFATE 40 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| HF Acquisition Co LLC, DBA HealthFirst | GENTAMICIN SULFATE 40 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Hospira, Inc. | GENTAMICIN SULFATE 40 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Fresenius Kabi USA, LLC | GENTAMICIN SULFATE 40 mg/mL | Jul 15, 2026 | Aug 28, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Gentamicin Sulfate — NDC 55154-2392-05," retrieved September 3, 2026, https://drugdashboards.com/drug/55154239205.
Free to cite with attribution — see how the data is put together.